Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer

Molecular Imaging and Biology

Volumn 18, Issue 2, 2016, Pages 258-266

  Tago, Tetsuro ^a   Furumoto, Shozo ^a   Okamura, Nobuyuki ^b   Harada, Ryuichi ^a   Adachi, Hajime ^a   Ishikawa, Yoichi ^a   Yanai, Kazuhiko ^b   Iwata, Ren ^a   Kudo, Yukitsuka ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer s disease; Positron emission tomography; Stereoisomerism; Tau proteins

Indexed keywords

1,2 ISOPROPYLIDENEGLYCEROL; AMYLOID BETA PROTEIN; FLUORINE 18; IODINATED GLYCEROL; TAU PROTEIN; TRACER; UNCLASSIFIED DRUG; [FLUORINE 18]THK 5105; ANILINE DERIVATIVE; QUINOLINE DERIVATIVE; THK5105;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN HOMOGENATE; CHIRALITY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; ENANTIOMER; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RADIOACTIVITY; RADIOCHEMISTRY; ALZHEIMER DISEASE; ANIMAL; BLOOD; BRAIN; CHEMISTRY; DIAGNOSTIC IMAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METABOLOME; PROCEDURES; STEREOISOMERISM;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; ANIMALS; AUTORADIOGRAPHY; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; METABOLOME; MICE; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; RADIOACTIVE TRACERS; RADIOACTIVITY; STEREOISOMERISM; TAU PROTEINS;

EID: 84959912123     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-015-0879-8     Document Type: Article

References (37)

1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189
2. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biology 8:101–12
3. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–6
4. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112–9
5. Jack CR, Knopman DS, Jagust WJ et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–16
6. Rowe CC, Villemagne VL (2013) Brain amyloid imaging. J Nucl Med Tech 41:11–8
7. Villemagne V, Furumoto S, Fodero-Tavoletti MT et al (2012) The challenges of tau imaging. Future Neurol 7:409–421
8. Svedberg MM, Rahman O, Hall H (2012) Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer’s disease. Nucl Med Biol 39:484–501
9. Jensen JR, Cisek K, Funk KE et al (2011) Research towards tau imaging. J Alzheimer’s Dis 26:147–57
10. Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131:1630–45
11. Clark CM, Schneider JA, Bedell BJ et al (2011) Use of florbetapir-PET for imaging. JAMA 305:275–284
12. Wolk DA, Grachev ID, Buckley C et al (2011) Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 68:1398–403
13. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42:631–631
14. Akoury E, Pickhardt M, Gajda M et al (2013) Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew Chem Int Ed 52:3511–5
15. Chien DT, Bahri S, Szardenings AK et al (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimer’s Dis 34:457–68
16. Zhang W, Arteaga J, Cashion DK et al (2012) A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimer’s Dis 31:1–12
17. Kepe V, Bordelon Y, Boxer A et al (2013) PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimer’s Dis 36:145–53
18. Maruyama M, Shimada H, Suhara T et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108
19. Okamura N, Suemoto T, Furumoto S et al (2005) Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease. J Neurosci 25:10857–62
20. Fodero-Tavoletti MT, Okamura N, Furumoto S et al (2011) 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 134:1089–100
21. Harada R, Okamura N, Furumoto S et al (2013) Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging 40:125–132
22. Tago T, Furumoto S, Okamura N et al (2014) Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. J Labelled Compd Radiopharm 57:18–24
23. Okamura N, Furumoto S, Harada R et al (2013) Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54:1420–7
24. Okamura N, Furumoto S, Fodero-Tavoletti MT et al (2014) Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137:1762–71
25. Simonyi M, Fitos I, Visy J (1986) Chirality of bioactive agents in protein binding storage and transport processes. Trends Pharmacol Sci 7:112–116
26. Nau C, Strichartz GR (2002) Drug chirality in anesthesia. Anesthesiology 97:497–502
27. Mizuta T, Kitamura K, Iwata H et al (2008) Performance evaluation of a high-sensitivity large-aperture small-animal PET scanner: ClairvivoPET. Ann Nucl Med 22:447–55
28. 18F]fluorohydrins. J Am Chem Soc 136:5291–4
29. Bulic B, Pickhardt M, Mandelkow E (2013) Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem 56:4135–55
30. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–59
31. 11)C]AZD2995 and [ (11)C]AZD2184 in Alzheimer’s disease patients. Eur J Nucl Med Mol Imaging 40:580–93
32. Mathis CA, Wang Y, Holt DP et al (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740–2754
33. Ishiwata K, Kawamura K, Yanai K, Hendrikse NH (2007) In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med 48:81–7
34. Barraud de Lagerie S, Comets E, Gautrand C et al (2004) Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br J Pharmacol 141:1214–22
35. Price JC, Klunk WE, Lopresti BJ et al (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25:1528–47
36. Nguyen LA, He H, Pham-Huy C (2006) Chiral drugs: an overview. Int J Biomed Sci 2:85–100
37. Matsumura A, Mizokawa S, Tanaka M et al (2003) Assessment of microPET performance in analyzing the rat brain under different types of anesthesia: comparison between quantitative data obtained with microPET and ex vivo autoradiography. NeuroImage 20:2040–2050